1272353-82-8
1272353-82-8
Chemical Structure
BMS-919373
- CAS No.: 1272353-82-8
- Formula:C25H20N6O2S
- Molecular Weight:468.53
IUPAC Name: 5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridine-3-sulfonamide
InChIKey: XGKULQQVQWCASY-UHFFFAOYSA-N
SMILES: O=S(C1=CC(C2=NC(NCC3=NC=CC=C3)=C4C(C5=CC=CC=C5)=CC=CC4=N2)=CN=C1)(N)=O
Biological Activity: BMS-919373 is a selective, potent IKur current blocker. BMS-919373 can be used for the research of cardiovascular diseases[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BMS-919373 | 98.50% | BMS-919373 is a selective, potent IKur current blocker. BMS-919373 can be used for the research of cardiovascular diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SRI-31040 | SRI-31040 is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SRI-31142 | 99.89% | SRI-31142 is a putative, brain-penetrant allosteric inhibitor of the dopamine transporter (DAT). In behavioral studies using intracranial self-stimulation (ICSS), SRI-31142 did not produce the abuse-related effects seen with cocaine and GBR-12935, but instead reduced ICSS responses and dopamine levels in the nucleus accumbens (NAc) at effective doses. SRI-31142 also blocked cocaine-induced increases in ICSS and NAc dopamine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SRI-29574 | SRI-29574 is an allosteric modulator of the dopamine transporter (DAT). SRI-29574 partially inhibits the uptake of the DAT (IC50=2.3 nM) and also partially inhibits the uptake of the serotonin transporter (SERT) and norepinephrine transporter (NET). SRI-29574 may serve as a useful probe to study the function and regulatory mechanisms of DAT. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TGFβ-IN-5 | 99.22% | TGFβ-IN-5 is a type I transforming growth factor-β receptor (TGF-β R1) kinase inhibitor with an IC50 value of 0.0485 μM. TGFβ-IN-5 reverses the effect of TGF-β-mediated cell activation on the expression of fibrosis-related genes. TGFβ-IN-5 can be used in the research of fibroproliferative diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PI5P4Ks-IN-2 | 99.78% | PI5P4Ks-IN-2 is a inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ). PI5P4Ks-IN-2 targets to PI5P4K isoforms with pIC50 values of <4.3 (PI5P4Kα), <4.6 (PI5P4Kβ), 6.2 (PI5P4Kγ), 0.32 (PI5P4Kγ+), respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PDE5-IN-9 | 98.0% | PDE5-IN-9 (Compound 59) is a PDE5 inhibitor (IC50: 11.2 μM). PDE5-IN-9 shows interaction with Gln 817, Tyr 612, and Ala 767 amino acid residues. PDE5-IN-9 can be used for research of cardiovascular disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Heme Oxygenase-1-IN-3 | Heme Oxygenase-1-IN-3 (compound 4) is a highly selective heme oxygenase-1 (HO-1) inhibitor (Kd=141 nM) that can be used in the research of cancer and neurodegenerative diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UNI418 | 99.61% | UNI418 is an orally active and potent PIKfyve and PIP5K1C inhibitor with Kd values of 0.78 and 61 nM, respectively. UNI418 exhibits anti-SARS-CoV-2 activity with an EC50 of 1.4 μM. UNI418, through inhibition of PIKfyve and PIP5K1C (IC50 = 60.1 nM), on one hand reduces IP6 levels to trigger Cul4A-WDR5-dependent homologous recombination protein degradation, and on the other hand impairs endolysosomal acidification, cathepsin L maturation, and ACE2-mediated endocytosis, thereby blocking SARS-CoV-2 entry and escape. UNI418 can be used for research on ovarian cancer and SARS-CoV-2 infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EGFR-IN-146 | EGFR-IN-146 is an EGFR inhibitor that can inhibit the EGFR signaling pathway and improve insulin sensitivity by activating the AMPK pathway, which can effectively reduce blood sugar levels and body weight. EGFR-IN-146 has great potential in the study of diabetes and obesity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NRAS-G4-ligand-1 | 90.0% | NRAS-G4-ligand-1 is a NRAS-G4 binder with Kd values of 0.25 μM (AlexaFluor 647-labeled) and 0.932 μM (biotinylated), respectively. NRAS-G4-ligand-1 acts as a translation inhibitor, reduces cancer cell viability, and downregulates NRAS protein levels. NRAS-G4-ligand-1 can be used in the research of melanoma and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
